Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia
This study has been completed.
Children's Oncology Group
Information provided by:
National Cancer Institute (NCI)
First received: May 14, 2004
Last updated: November 20, 2010
Last verified: November 2010
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||No date given|
|Estimated Primary Completion Date:||No date given|
Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM; Children's Oncology Group Study. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 1;25(31):4922-8.
Horton TM, Dolan E, Hegde M, et al.: A phase I study of temozolomide (Temodar®) in pediatric patients with relapsed or refractory leukemia: a Children's Oncology Group study. [Abstract] Blood 106 (11): A-4455, 2005.